1
|
Lee H, Machado CRL, Hammaker D, Choi E, Prideaux EB, Wang W, Boyle DL, Firestein GS. Joint-specific regulation of homeobox D10 expression in rheumatoid arthritis fibroblast-like synoviocytes. PLoS One 2024; 19:e0304530. [PMID: 38829908 PMCID: PMC11146700 DOI: 10.1371/journal.pone.0304530] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2023] [Accepted: 05/14/2024] [Indexed: 06/05/2024] Open
Abstract
Rheumatoid arthritis (RA) is a systemic immune-mediated disease characterized by joint inflammation and destruction. The disease typically affects small joints in the hands and feet, later progressing to involve larger joints such as the knees, shoulders, and hips. While the reasons for these joint-specific differences are unclear, distinct epigenetic patterns associated with joint location have been reported. In this study, we evaluated the unique epigenetic landscapes of fibroblast-like synoviocytes (FLS) from hip and knee synovium in RA patients, focusing on the expression and regulation of Homeobox (HOX) transcription factors. These highly conserved genes play a critical role in embryonic development and are known to maintain distinct expression patterns in various adult tissues. We found that several HOX genes, especially HOXD10, were differentially expressed in knee FLS compared with hip FLS. Epigenetic differences in chromatin accessibility and histone marks were observed in HOXD10 promoter between knee and hip FLS. Histone modification, particularly histone acetylation, was identified as an important regulator of HOXD10 expression. To understand the mechanism of differential HOXD10 expression, we inhibited histone deacetylases (HDACs) with small molecules and siRNA. We found that HDAC1 blockade or deficiency normalized the joint-specific HOXD10 expression patterns. These observations suggest that epigenetic differences, specifically histone acetylation related to increased HDAC1 expression, play a crucial role in joint-specific HOXD10 expression. Understanding these mechanisms could provide insights into the regional aspects of RA and potentially lead to therapeutic strategies targeting specific patterns of joint involvement during the course of disease.
Collapse
Affiliation(s)
- Hyeonjeong Lee
- Division of Rheumatology, Allergy and Immunology, School of Medicine, University of California San Diego, La Jolla, California, United States of America
| | - Camilla R. L. Machado
- Division of Rheumatology, Allergy and Immunology, School of Medicine, University of California San Diego, La Jolla, California, United States of America
| | - Deepa Hammaker
- Division of Rheumatology, Allergy and Immunology, School of Medicine, University of California San Diego, La Jolla, California, United States of America
| | - Eunice Choi
- Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, California, United States of America
| | - Edward B. Prideaux
- Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, California, United States of America
| | - Wei Wang
- Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, California, United States of America
| | - David L. Boyle
- Division of Rheumatology, Allergy and Immunology, School of Medicine, University of California San Diego, La Jolla, California, United States of America
| | - Gary S. Firestein
- Division of Rheumatology, Allergy and Immunology, School of Medicine, University of California San Diego, La Jolla, California, United States of America
| |
Collapse
|
2
|
Gomoll AH, Diduch DR, Flanigan DC, Ranawat AS, Slynarski K, Walawski J, Crawford DC. An implantable shock absorber yields an 85% survival-from-arthroplasty rate through 5 years in working-age patients with medial compartment knee osteoarthritis. Knee Surg Sports Traumatol Arthrosc 2023:10.1007/s00167-023-07373-4. [PMID: 36951981 DOI: 10.1007/s00167-023-07373-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/12/2022] [Accepted: 02/25/2023] [Indexed: 03/24/2023]
Abstract
PURPOSE To evaluate the 5-year rate of survival without undergoing arthroplasty or high tibial osteotomy (HTO) in subjects with mild-to-moderate medial compartment knee osteoarthritis (OA) who were treated with an implantable shock absorber (ISA) system. METHODS Three prospective, sequential, multicenter, international, single-arm clinical trials were conducted comprising subjects who received an ISA for symptomatic medial knee OA after failing ≥ 6 months of conservative therapy. Study outcomes were analyzed cumulatively and by enrollment group when all subjects' follow-up data exceeded the 2-year threshold after ISA implantation. Primary outcome was survival rate without conversion to arthroplasty/HTO. Secondary outcomes were changes in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain and function scores after ISA implantation. RESULTS All 171 enrolled subjects (age 51 ± 9 years, body-mass index 28.5 ± 3.5 kg/m2, 38% female; study knee Kellgren-Lawrence score 2.7 ± 0.9 points) were followed for a minimum of 2, and up to 5, years after device implantation. Overall, 90.6% (155/171) of subjects survived without requiring arthroplasty/HTO at last follow-up (mean 3.2 ± 1.6 years). The Kaplan-Meyer median 3- and 5-year survival-without-arthroplasty point estimates were 89.8% (95% CI 86.5‒95.7%) and 84.9% (95% CI 75.1‒91.1%), respectively. The median 3-year estimated survival rate for the most recent study (n = 81) was 97.3%. The mean WOMAC Pain score decreased 71% from baseline to last follow-up after ISA implantation, from 58 ± 13 to 16 ± 17 points (p < 0.0001). The Function score improved 69%, decreasing from 56 ± 18 to 17 ± 17 points (p < 0.0001). CONCLUSIONS In younger patients with mild-to-moderate symptomatic medial compartment knee OA, implantation of the ISA device resulted in a 5-year survival rate of 85% from undergoing arthroplasty or HTO. The ISA system may be an effective treatment option for working-age patients with medial knee OA who are not candidates for or do not desire more invasive surgical approaches. LEVEL OF EVIDENCE II.
Collapse
Affiliation(s)
- Andreas H Gomoll
- Hospital for Special Surgery, 535 East 70th Street, New York, NY, 10021, USA.
| | - David R Diduch
- Department of Orthopaedic Surgery, University of Virginia, Charlottesville, VA, USA
| | - David C Flanigan
- Wexner Medical Center & Department of Orthopaedic Surgery, Ohio State University, Columbus, OH, USA
| | - Anil S Ranawat
- Hospital for Special Surgery, 535 East 70th Street, New York, NY, 10021, USA
| | | | | | - Dennis C Crawford
- Department of Orthopedics & Rehabilitation, Oregon Health & Science University, Portland, OR, USA
| |
Collapse
|
3
|
Morse KW, Heinz NK, Abolade JM, Wright-Chisem J, Alice Russell L, Zhang M, Mirza S, Pearce-Fisher D, Orange DE, Figgie MP, Sculco PK, Goodman SM. Factors Associated With Increasing Length of Stay for Rheumatoid Arthritis Patients Undergoing Total Hip Arthroplasty and Total Knee Arthroplasty. HSS J 2022; 18:196-204. [PMID: 35645648 PMCID: PMC9096994 DOI: 10.1177/15563316221076603] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/01/2021] [Accepted: 11/05/2021] [Indexed: 12/12/2022]
Abstract
Background: Total hip arthroplasty (THA) and total knee arthroplasty (TKA) are cost-effective procedures that decrease pain and improve health-related quality of life for patients with advanced symptomatic arthritis, including rheumatoid arthritis (RA). Patients with RA have a longer length of stay (LOS) after THA or TKA than patients with osteoarthritis, yet the factors contributing to LOS have not been investigated. Purpose: We sought to identify the factors contributing to LOS for patients with RA undergoing THA and TKA at a single tertiary care orthopedic specialty hospital. Methods: We retrospectively reviewed data from a prospectively collected cohort of 252 RA patients undergoing either THA or TKA. Demographics, RA characteristics, medications, serologies, and disease activity were collected preoperatively. Linear regression was performed to explore the relationship between LOS (log-transformed) and possible predictors. A multivariate model was constructed through backward selection using significant predictors from a univariate analysis. Results: Of the 252 patients with RA, 83% were women; they had a median disease duration of 14 years and moderate disease activity at the time of arthroplasty. We had LOS data on 240 (95%) of the cases. The mean LOS was 3.4 ± 1.5 days. The multivariate analysis revealed a longer LOS for RA patients who underwent TKA versus THA, were women versus men, required a blood transfusion, and took preoperative opioids. Conclusion: Our retrospective study found that increased postoperative LOS in RA patients undergoing THA or TKA was associated with factors both non-modifiable (type of surgery, sex) and modifiable (postoperative blood transfusion, preoperative opioid use). These findings suggest that preoperative optimization of the patient with RA might focus on improving anemia and reducing opioid use in efforts to shorten LOS. More rigorous study is warranted.
Collapse
Affiliation(s)
- Kyle W. Morse
- Department of Medicine, Hospital for
Special Surgery, New York, NY, USA,Kyle W. Morse, MD, Department of Medicine,
Hospital for Special Surgery, 535 E 70th St., New York, NY 10021, USA.
| | - Nicole K. Heinz
- Department of Medicine, Hospital for
Special Surgery, New York, NY, USA
| | - Jeremy M. Abolade
- Department of Medicine, Hospital for
Special Surgery, New York, NY, USA
| | | | - Linda Alice Russell
- Department of Medicine, Hospital for
Special Surgery, New York, NY, USA,Department of Medicine, Weill Cornell
Medicine, New York, NY, USA
| | - Meng Zhang
- Department of Medicine, Feinstein
Institutes for Medical Research, Northwell Health, Manhasset, NY, USA
| | - Serene Mirza
- Department of Medicine, Hospital for
Special Surgery, New York, NY, USA
| | | | - Dana E. Orange
- Department of Medicine, Hospital for
Special Surgery, New York, NY, USA,Rockefeller University, New York, NY,
USA
| | - Mark P. Figgie
- Department of Medicine, Hospital for
Special Surgery, New York, NY, USA,Department of Medicine, Weill Cornell
Medicine, New York, NY, USA
| | - Peter K. Sculco
- Department of Medicine, Hospital for
Special Surgery, New York, NY, USA,Department of Medicine, Weill Cornell
Medicine, New York, NY, USA
| | - Susan M. Goodman
- Department of Medicine, Hospital for
Special Surgery, New York, NY, USA,Department of Medicine, Weill Cornell
Medicine, New York, NY, USA
| |
Collapse
|